What is JANX's current stock price?

JANX (Janux Therapeutics, Inc.) is currently trading at $14.52 with a market cap of $885.5M.

What sector is Janux Therapeutics, Inc. in?

Janux Therapeutics, Inc. (JANX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is JANX a good stock to buy?

Analysts have a Buy consensus on JANX with a price target of $28.57. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

JANX Janux Therapeutics, Inc.

Healthcare

$14.52+0.76%ClosedMarket Cap: $885.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.97

P/S

40.97

EV/EBITDA

-6.40

DCF Value

$-2.98

FCF Yield

-8.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

54.1%

Operating Margin

-726.3%

Net Margin

-529.7%

ROE

-11.8%

ROA

-11.1%

ROIC

-16.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.7M	$-24.4M	$—
Q4 null	$7.9M	$-31.9M	$—
FY null	$10.0M	$-113.6M	$—
Q3 null	$10.0M	$-24.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$28.57

Target (Median)

$30.00

Target Range

$14.00 - $45.00

2 Strong Buy13 Buy2 Hold0 Sell1 Strong Sell

Piper SandlerOverweight

2026-05-08

WedbushOutperform

2026-05-08

GuggenheimBuy

2026-05-08

Jones TradingBuy

2026-04-28

BarclaysUnderweight

2026-04-20

Trading Activity

Insider Trades

View All

Dobek Mariaofficer: Vice President, Accounting

SellWed May 13

Go Williamofficer: Chief Medical Officer

SellWed Feb 04

Go Williamofficer: Chief Medical Officer

SellWed Feb 04

Go William

SellWed Feb 04

Meyer Andrew Hollmanofficer: Chief Business Officer

SellFri Jan 02

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.57

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Peers